Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Investor Presentation (August 2023)
14 slides from Atomo Diagnostics's investor presentation, Aug 24, 2023
Slide 1: Atomo Diagnostics (ASX:AT1)
For personal use only ATOMO DIAGNOSTICS (ASX:AT1)
Slide 2: Who is Atomo and what does it do?
WHO IS ATOMO AND WHAT DOES IT DO? Atomo’s portfolio of tests and technologies allows people to test early and test often, putting healthcare in the hands of the consumer WHO IS ATOMO? WHAT DO WE DO? For personal use only Headquartered in Australia and listed on the ASX, Atomo Atomo’s strategic focus
Slide 3: Atomo's business: de-risked, validated and scaling
ATOMO’S BUSINESS: DE-RISKED, VALIDATED AND SCALING PRODUCT RISK REVENUE / SALES RISK MARKET RISK REGULATORY RISK STATUS STATUS STATUS STATUS Designed to address user challenges with Increasing HIV test sales, existing OEM Key stakeholders now support home testing with Class IV (highest) approvals in
Slide 4: Key achievements for FY23
KEY ACHIEVEMENTS FOR FY23 Finished Test Products Business: • Atomo entered into new HIV agreements to secure a $1.9m take or pay deal for the South African private sector and an initial order for the UK retail market worth $910k with a larger follow-on order contracted prior to 30 December 2023 For
Slide 5: FY23 – Profit & Loss
FY23 – PROFIT & LOSS • Total customer revenue of $2.54m is lower than the prior financial period as the COVID-19 AUD FY23($m) FY22($m) (%) pandemic passed, and with it, demand for COVID-19 rapid antigen and rapid antibody tests. Revenue 2.54 12.34 (79%) • After normalizing for COVID-19 sales, revenu
Slide 6: FY23 – Balance sheet and cash flow
FY23 – BALANCE SHEET AND CASH FLOW AUD FY23 ($m) FY22 ($m) Cash and cash equivalents 6.47 12.97 Trade and other receivables 1.82 2.68 For personal use only Inventories 2.14 3.42 Property, plant and equipment 2.50 3.67 Intangible assets 3.30 3.57 Other assets 0.23 0.32 Total assets 16.47 26.63 Trade
Slide 7: Atomo leads disruptive innovation in rapid testing
ATOMO LEADS DISRUPTIVE INNOVATION IN RAPID TESTING Atomo has developed best-in-class rapid tests that transform ease of use and reliability For personal use only “I would rather pay for this test in future (than use a free test) if it “The lancet would not be out of place in a Christmas cracker” mea
Slide 8: Drivers of the adoption of rapid testing
DRIVERS OF THE ADOPTION OF RAPID TESTING Adoption of decentralised testing driven by ease of use, speed and accessibility 1 WHAT DRIVES ADOPTION OF RAPID TESTING ATOMO’S PASCAL DEVICE VS. COMPETITORS An independent study was conducted to validate Atomo’s Pascal device usability when compared to a st
Slide 9: The home test market - responding to consumer demand
THE HOME TEST MARKET - RESPONDING TO CONSUMER DEMAND New and incumbent industry players increasingly focused on at-home consumer test market Consumer-Initiated Testing $250M Revenues by 2025 For personal use only * The slide depicts general examples, not only specific Atomo Diagnostics products, cus
Slide 10: Atomo's HIV self test commercialised and sold globally
ATOMO’S HIV SELF TEST COMMERCIALISED AND SOLD GLOBALLY Atomo has developed and successfully launched the world’s first integrated, blood-based HIV Self Test which is now registered in 46 countries with over 1.5 million units sold* For personal use only With regulatory approvals Finished product asse
Slide 11: Pregnancy market opportunity
PREGNANCY MARKET OPPORTUNITY Atomo’s early detection pregnancy test has a material opportunity to create a premium niche in the valuable female healthcare market GLOBAL PREGNANCY TESTING MARKET SIZE1 (REVENUE AUD2) ATOMO’S OPPORTUNITY The Atomo blood-based pregnancy test has significant benefits, ad
Slide 12: Future product roadmap
FUTURE PRODUCT ROADMAP Atomo has a strong pipeline of product development moving beyond infectious diseases to target women’s health and at-home wellness monitoring 2024 2025 AND BEYOND IRON DEFICIENCY / FERRITIN VITAMIN D OTHER APPLICATIONS For personal use only Atomo is seeking to expand its finis
Slide 13: Strategy and priorities for FY24 and beyond
STRATEGY AND PRIORITIES FOR FY24 AND BEYOND ATOMO STRATEGY: • Continue to establish Atomo’s products and partner supported products as offering unmatched usability and reliability in key markets, including ongoing focus outside of LMICs where better margins can be secured For personal use only • Bec
Slide 14: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on made available to the recipient in connection with the opportunity outlined in this presentation and information available as at the date of this presentation. The information in this presentation is provi
Atomo Diagnostics — Investor Presentation (August 2023) on 6ix